MPAP
Methylenedioxyphenyl monoamine activity enhancer (MAE), BPAP relative, experimental.
Pharmacology
Contents
WHAT IS MPAP?
Detailed overview
MPAP (methylenedioxyphenylpropylaminopentane, 1-(3,4-methylenedioxyphenyl)-2-propylaminopentane) is a monoamine activity enhancer (MAE) from the propylaminopentane series developed by Jozsef Knoll, in which a benzodioxole ring replaces the phenyl ring of PPAP and the benzofuran ring of BPAP. MAEs do not release neurotransmitters; instead they increase the amount released per nerve impulse, so they strengthen signaling only when the neuron is already active. Like BPAP, MPAP enhances serotonin, norepinephrine and dopamine with roughly equal potency, in contrast to PPAP and selegiline, which act exclusively as catecholaminergic activity enhancers (CAEs). There is no MPAP-specific human or clinical data; the compound exists only as an unregulated experimental research chemical.
Mechanism
MAE (serotonin + catecholamine), presynaptic
Evidence
Reference-level (no MPAP-specific study)
Legal status
Unapproved research chemical
Receptor profile
- Catecholamine / serotonin activity (impulse-linked)Strong
- TAAR1 (intracellular trace amine receptor)Moderate
- Dopamine / norepinephrine toneWeak
Safety
Side effects, stop signs, contraindications
Side effects · 6
- No MPAP-specific human safety data: the profile is inferred almost entirely from related compounds (BPAP, PPAP) and anecdote
- Possible mild stimulation, restlessness or sleep disturbance due to enhanced catecholaminergic activity
- Mood shifts, irritability or anxiety possible, since it also enhances serotonin activity (broader monoaminergic effect than PPAP)
- Narrow, bell-shaped (inverted-U) dose-response: more is not better and too high a dose may abolish the effect
- Given the hepatotoxicity signal documented for BPAP, theoretical liver strain cannot be excluded by analogy
- Unknown long-term safety profile, consequences of chronic use are not studied
Contraindications · 5
- Avoid during pregnancy and breastfeeding, no safety data available
- Avoid combining with other monoaminergic agents (antidepressants, MAO inhibitors, stimulants) due to risk of serotonergic or catecholaminergic excess
- Caution advised with cardiovascular disease or hypertension due to the noradrenergic effect
- Caution warranted with liver disease or elevated liver enzymes given the related compound's hepatotoxicity signal
- Unapproved, experimental-only compound, human dosing and safety standards are not established
Related Nootropics
Same therapeutic category
FAQ
FAQ
Methylenedioxyphenyl monoamine activity enhancer (MAE), BPAP relative, experimental.
Telegram
Have a question about MPAP?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.